Kosugi Yohei, Yamamoto Syunsuke, Sano Noriyasu, Furuta Atsutoshi, Igari Tomoko, Fujioka Yasushi, Amano Nobuyuki
Drug Metabolism and Pharmacokinetics Research Laboratories, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited, Kanagawa, Japan.
J Pharm Sci. 2015 Sep;104(9):2887-93. doi: 10.1002/jps.24401. Epub 2015 Feb 26.
We attempted to establish animal models to evaluate the effects of drug degradation in the stomach on oral bioavailability. In addition, we assessed the utilization of animal studies in determining the need for enteric-coated formulations. In order to control the gastric pH in rats and dogs, appropriate dosing conditions were investigated using pentagastrin and rabeprazole, which stimulate and inhibit gastric acid secretion. Using animals controlled for gastric acid secretion, the area under curve (AUC) ratios (AUC with rabeprazole/AUC with pentagastrin) of all compounds unstable under acidic conditions were evaluated. The AUC ratios of omeprazole and erythromycin, which are administered orally to humans, as enteric-coated tablets, were greater than 1.9 in the rats and dogs controlled for gastric acid secretion. On the contrary, the AUC ratios of clarithromycin, azithromycin, and etoposide (commercially available as a standard immediate-release form) were less than 1.3 each. In conclusion, in vivo models using rats and dogs were optimized to evaluate the effects of gastric acid on the oral bioavailability of drugs, and demonstrated that in vivo models can lead to a better understanding of the oral bioavailability, with respect to the formulation development.
我们试图建立动物模型,以评估药物在胃中的降解对口服生物利用度的影响。此外,我们评估了动物研究在确定肠溶包衣制剂需求方面的应用。为了控制大鼠和狗的胃内pH值,使用刺激和抑制胃酸分泌的五肽胃泌素和雷贝拉唑研究了合适的给药条件。利用胃酸分泌得到控制的动物,评估了所有在酸性条件下不稳定的化合物的曲线下面积(AUC)比值(雷贝拉唑组AUC/五肽胃泌素组AUC)。在胃酸分泌得到控制的大鼠和狗中,口服给人类的肠溶衣片奥美拉唑和红霉素的AUC比值大于1.9。相反,克拉霉素、阿奇霉素和依托泊苷(市售为标准速释剂型)的AUC比值均小于1.3。总之,使用大鼠和狗的体内模型经过优化,可用于评估胃酸对药物口服生物利用度的影响,并表明体内模型有助于在制剂研发方面更好地理解口服生物利用度。